Patients with significant systemic activity are generally patients with early onset disease, antinuclear antibodies (ANA) positivity with a higher frequency of anti-Ro/SSA (with or without anti-La/SSB), low C3, low C4 and cryoglobulinemia [154,276,277,298]. This evidence concerns the gene C4A and cryoglobulinemia.